GSK, Teva Say Lamictal IP Licensing Deal Wasn't Conspiracy
GlaxoSmithKline LLC and Teva Pharmaceuticals USA Inc. urged a New Jersey federal judge on Wednesday to dismiss a putative class action that accuses them of conspiring to keep a generic epilepsy...To view the full article, register now.
Already a subscriber? Click here to view full article